Inflammatory Bowel Disease and Gut Microbiota Current Strategies and Future Prospects in Nanomedicine

1. Introduction to Gut Microbiota and Inflammatory Bowel Disease: A Systematic Review

Rukshana Irani, Aniruddha Sen, Jagriti, and Ayan Chatterjee

2. Pathogenesis of Gut Microbiota in Inflammatory Bowel Disease

Kuttiappan Anitha, Santenna Chenchula, Shvetank Bhatt, Naveen Kumari Kopineni, Chikatipalli Radhika, and Krishna Chaitanya Amerneni

3. Impact of Nutraceuticals on Gut Microbiota for the Management of Inflammatory Bowel Disease

Ushasi Das, Monika Kaushik, Neeraj Mishra, Himanshu Sharma, Subhajit Mandal, Popat Mohite, Aritra Banerjee, Farzad Taghizadeh-Hesary, Raju Kundavaram, Radheshyam Pal,  and Sumel Ashique

4. Targeting Gut Microbiota with a Novel Drug Delivery System to Treat Inflammatory Bowel Disease

Pavani Sriram, Shvetank Bhatt, and Ashish Suttee

5. Management of Gut Microbiota-Derived Bacterial Metabolites Induced Inflammatory Bowel Disease

Monika Vishwakarma, Poornima Agarwal, Md. Faheem Haider, Tanweer Haider, and Vandana Soni

6. Correlation Between Host Genetics and Gut Microbiota in Inflammatory Bowel Disease

Manish Kumar, Vir Vikram Sharma, Subh Naman, Abhishek Tiwari, and Varsha Tiwari

7. Oral siRNA-Based Nanomedicine for the Treatment of Inflammatory Bowel Disease

S. Upadhyay, S. Soni, T. Shukla, and S. P. Pandey

8. Site-Specific Targeted Novel Drug Delivery System for the Management of Inflammatory Bowel Disease

Piyush Singhal, Nusrat Khan, Ravi Verma, and Kantrol Kumar Sahu

9. Surface-Modified Lipid Nanoparticle-Mediated Site-Specific Drug Delivery for Inflammatory Bowel Disease

Ankita Dadwal and Bhupinder Kumar

10. Interplay Between Autophagy, Gut Microbiota, and Inflammatory Bowel Disease

Arghya Kusum Dhar, Dilipkumar Reddy Kandula, and Narahari N. Palei

11. Role of Reactive Oxygen Species, Superoxide Dismutases, and Inflammation in Association with Gut Microbiota and Inflammatory Bowel Disease

Md. Khokon Miah Akanda, Sanzia Mehjabin, A. H. M. Nazmul Hasan, and G. M. Masud Parvez

12. Composition of Gut Microbiota Dysbiosis and Functional Food to Treat Inflammatory Bowel Disease

Ashish Garg, Sumel Ashique, Vishal Singh, Gopal Rai, Vijay Sagar Madamsetty, Neeraj Mishra, Naveen Sharma, and Shubneesh Kumar

13. Age-Related Gut Dysbiosis and Its Impact on Inflammatory Bowel Disease

Sagnik Nag, Arghyadeep Bhattacharjee, Purva Suhas Shirke, Rhujuta Anand Joshi, Aparajita Bagchi, Rashmi Pejakala Raveendra, and Oindrilla Mukherjee

14. Impact of Diseased Condition on Gut Microbiota in Inflammatory Bowel Disease

Sabiha Naz, Shweta Singh, and Tanushree Chaterjee

15. Role of Probiotics and Prebiotics in Inflammatory Bowel Disease

Pankaj Sharma, Wasim Akram, Navneet Garud, and Mukul Tailang

16. Application of Natural Products in Targeting Gut Microbiota for Inflammatory Bowel Disease Management

Andleeb Rehman, Nihad Ashraf Khan, Saliha Rizvi, and Gowhar Rashid

17. Future Prospects and Patents of Nanomedicines in Treating Inflammatory Bowel Disease

Londhe Sachin Bhimrao, Paul Gajanan Balaji, Amit Kumar, Rupsee Jain, and Awesh K. Yadav

Biography

Neeraj Mishra, PhD, is a Professor at the Amity Institute of Pharmacy, Gwalior, India. He has 20 years of teaching and research experience. A brand ambassador at Bentham Science, he has published more than 100 papers on recent concepts of novel drug delivery systems, oral delivery of synbiotics, localized drug delivery, targeted and controlled drug delivery of nanocarriers/microparticles for the treatment of breast and colon cancer, and neurodegenerative disorders. He has also written more than 15 books and 25 book chapters and has been granted several patents. He was a recipient of an Indian Council of Medical Research Senior Research Fellowship and a Distinguished Professor Award from the Indian Department of Science and Technology, National Science and Technology Management Information System, Synergizing Pharma Academic-Industry Collaboration Systems.

Sumel Ashique, MPharm, is a Research Scholar at the School of Pharmaceutical Sciences at Lovely Professional University, Punjab, India, where he is pursuing his PhD. His research area is probiotics, postbiotics, gut microbiota, and inflammatory disorders. With knowledge in drug delivery, nanotechnology, and targeted treatment strategy, he has four years of teaching experience and has published book chapters with international publishers and over 100 papers in accredited reputed journals. He has also six granted intellectual property (IP) patents from IP India and Australia. He is currently editing 13 books with Apple Academic Press, CRC Press, Taylor and Francis, and others.

Ashish Garg, PhD, is a Professor at the Guru Ramdas Khalsa Institute of Science and Technology (Pharmacy), Jabalpur, M.P., India. He has around ten years of teaching and research experience and has 80 publications in national and international journals of repute. He has authored 27 book chapters and edited several books on recent concepts of nanotechnology, novel drug delivery systems, cancer targeting, etc. Dr. Garg has been granted three international patents and has published three Indian patents. He also acts as an editorial board member and reviewer for several journals.